This R21 exploratory/developmental project in translational research aims to test the small-molecule necrostatin-1 (Nec-1) as a potential neuroprotective agent for the treatment of amyotrophic lateral sclerosis (ALS), an incurable fatal paralytic disorder. Mutations in superoxide dismutase-1 (SOD1) cause familial ALS and studies in chimeric or conditional mutant mice indicate that non-neuronal cells play an important role in mutant SOD1-related neurodegeneration. We and others find that wild-type primary spinal motor neurons (MNs) are selectively killed by mutant SOD1-expressing astrocytes or their conditioned medium by programmed cell death. Now, we show that Nec-1, an allosteric inhibitor of the kinase receptor interacting protein-1 (RIP1), protects against this mutant astrocyte-induced MN death. Thus, to define the cellular target of Nec- 1, specific aim (SA)-1 will determine whether the protection afforded by Nec-1 in our MN/astrocyte co-culture model system of ALS is linked to an inhibition of RIP1 within MNs and/or within astrocytes. Whether Nec-1 protects MN cell bodies as potently as their nerve processes will also be examined. We also find, by in silico modeling, that Nec-1 is predicted to cross the blood-brain barrier raising the possibility that Nec-1 may be usable in vivo as a therapeutic agent for ALS. Thus, in our initial steps toward testing this possibility, SA-2 will assess Nec-1 and its inactive structural analogue Nec-1ia solubility and stability in suitable vehicles for chronic in vivo use, and their central nervous system penetration, pharmacokinetics, routes of administration and tolerability in wild- type mice. Then, based on the optimal conditions of Nec-1 administration defined in SA-2, SA-3 will determine the neuroprotective potency of Nec-1 in the transgenic mutant SOD1 mouse model of ALS using a comprehensive set of behavioral and morphological investigations. We anticipate that, by the end of this project, the preclinical suitability and effectiveness of Nec-1 will have been evaluated, which may lead into a therapeutic development project for ALS. The latter will include preclinical regulatory studies as part of the prerequisites for future clinical trials.

Public Health Relevance

Amyotrophic lateral sclerosis (ALS) is an incurable fatal paralytic disease in which inflammation is an increasingly recognized contributor to the disease process. We have found in a dish that a small molecule called necrostatin blocks the deleterious effects of specific inflammatory cells on the nerve cells responsible for ALS paralysis. Herein, we propose to determine the suitability of using this small molecule is a living organism and to demonstrate whether it is protective in an experimental model of ALS.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Gubitz, Amelie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Ikiz, Burcin; Alvarez, Mariano J; Ré, Diane B et al. (2015) The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. Cell Rep 12:335-45
Le Masson, Gwendal; Przedborski, Serge; Abbott, L F (2014) A computational model of motor neuron degeneration. Neuron 83:975-88
Re, Diane B; Le Verche, Virginia; Yu, Changhao et al. (2014) Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 81:1001-1008
Hirsch, Etienne C; Jenner, Peter; Przedborski, Serge (2013) Pathogenesis of Parkinson's disease. Mov Disord 28:24-30
de Vries, Rosa L A; Przedborski, Serge (2013) Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol Cell Neurosci 55:37-43
Phani, Sudarshan; Loike, John D; Przedborski, Serge (2012) Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S207-9
Becker, Dorothea; Richter, Judith; Tocilescu, Maja A et al. (2012) Pink1 kinase and its membrane potential (Delta?)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode. J Biol Chem 287:22969-87
Jackson-Lewis, Vernice; Blesa, Javier; Przedborski, Serge (2012) Animal models of Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S183-5
Gilkerson, Robert W; De Vries, Rosa L A; Lebot, Paul et al. (2012) Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum Mol Genet 21:978-90
Magrané, Jordi; Sahawneh, Mary Anne; Przedborski, Serge et al. (2012) Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci 32:229-42

Showing the most recent 10 out of 13 publications